Sweet sensors final presentation
 

Sweet sensors final presentation

on

  • 2,115 views

 

Statistics

Views

Total Views
2,115
Views on SlideShare
2,115
Embed Views
0

Actions

Likes
0
Downloads
19
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • ImmediacyInstant results gives a reaction time advantage over tests done in a lab settingInexpensiveBy taking tests out of the lab and letting patients do them at home, we can save insurance companies a lot of money. Potential advantage in emerging markets too. Multiple testsMultiple tests (markers) for the same health care issue (glucose and cholesterol for diabetics, for example) leverage the same device. This translates into cost advantage, efficiency for the patience and may improve compliance. Short and inexpensive development cyclesMakes it practical to develop POC tests for indications with small populations such as during drug clinical trials
  • Glucose meter manufacturer
  • Glucose meter manufacturer

Sweet sensors final presentation Sweet sensors final presentation Presentation Transcript

  • * Direct Read Out of Target Concentration! Drug/Targets of Patient Samples interest (Blood/Saliva/ Urine ) Personal Glucose Meter* Diagnostics platform leveraging personal glucose meters: Therapeutic drug monitoring (TDM) Clinical trial companion diagnostics Medical diagnosis of many diseases Environmental detection of contaminants ~100 GOOTB connections Gluco = Glucose Sentient = Responsive to, perceptive or aware
  • *
  • ** Diabetes patients were our initial target market * Existing glucose meter + need to measure HbA1c* Key value propositions * Low cost More frequent tests and * Home testing better diabetes management * Already have PGM Total available market = $1.2* Large market billion * Patient population is huge Serviceable Available Market = $600 million Target market = $120 million
  • Business Model Canvas #1 Yi Lu, Tian Lan Sweet Sensors Neil Kane 10-11--2011 Chris Sorensen Conferences Product R&D Diabetics At home Product supportsGlucose monitor QC Clinicians (in rural area) Convenient Patient manufacturers Marketing network/community Triage nurses Less exposure toKit manufacturers infectious diseases Pre-diabetics in the hospitalReagent suppliers Cheaper More frequent Retailers (Walgreen) IP Personnel Better indicator of Online vendors (Amazon) health (diabetic management) Direct sales Reagents Manufacture Disposable test kit (used repeatedly Licensing on a regular basis) FDA certification?
  • * (I) spent a lot of time, money looking at this (HbA1c) market for LifeScan – stay away. The best test is one where the result affects the behavior. Find a test where immediate results have value.
  • * “You might even have a flexible Drugs of Abuse Analyzer “Bank” which is actually a rack which holds a number of small individual analyzers.” “The “Holy Grail” now is matching drug dosages to individual patients based on a wide range of factors (age, weight, gender, ethnicity, body chemistry, etc.) So ONE DOSE DOES NOT FIT ALL”
  • * * Immediacy * Inexpensive/cost savings * Multiple tests * Short and inexpensive development cycles …….became our value propositions
  • * * Home monitoring of HbA1c does not meet immediacy requirement * Large effort is necessary to promote the usage of home HbA1c test kit in the US * Competition from product from Bayer * Large regulatory hurdle * One market that meets all the value propositions is drug monitoring during clinical trials and after the market
  • Business Model Canvas #4 Yi Lu, Tian Lan Sweet Sensors Neil Kane 10-25-2011 Chris Sorensen Conferences Product R&D ImmediacyGlucose monitor Out of clinic Diabetics QC Marketing Product support manufacturers- Abbott? Clinicians (in rural area) FDA approval for in Convenient Patient vitro diagnostics network/community Pre-diabeticsKit manufacturers Food safety andReagent suppliers security related Cheaper Drug monitoring KOL More frequent Retailers (Walgreen) IP Personnel Medical Products Distributors Pharmaceutical Cos Disposable test kit (used repeatedlyReagents Licensing on a regular basis)Manufacturing FDA approval for in Reimbursement strategy vitro diagnostics Licensing Sponsored development or JDA
  • Business Model Canvas #5 Yi Lu, Tian Lan, Brian Wong Sweet Sensors Neil Kane 11-01-2011 Chris Sorensen Conferences R&DPharmaceutical Pharmaceutical QCcompanies One to one companies for Immediacy Therapeutic DrugGlucometer/strip Long term Monitoring (TDM) Convenient monitoringmanufacturer and safer dosage Exclusive Pharmaceutical Cos IP Pharmaceutical Cos Personnel Licensing R&D Sales (to pharmaceutical companies)
  • * * Better drug monitoring reduces the costs of drug development * “One-drug-for-all” is gone; new drugs are more likely to be effective for certain patients at certain dosage. * They are willing to provide financial support * They only want to buy the final products * Therefore we need to find partners
  • * Glucose meter GlucoSentient, Inc. Pharmaceutical companies companies Provide the Meter targets Added value for meter engineering Key customers manufacturers Strip design Low cost, fast Key market FDA approval monitoring improves knowledge clinical trials for pharmaceutical
  • Business Model Canvas #7 Yi Lu, Tian Lan, Brian Wong Sweet Sensors Neil Kane 11-15-2011 Chris Sorensen Conferences R&DPharmaceutical Immediate results Pharmaceuticalcompanies Publicity companies for Direct Convenient monitoring Therapeutic Drug Insurance and safer dosage Monitoring (TDM)Glucometer mfr Long term ReimbursementStrip mfr Robust/extensible Diagnostic companiesDiagnostics Inexpensivecompanies Contract research Simple Pharmaceutical Cos organizations IP InvestorsContract researchorganizations Personnel Pharmaceutical Cos Licensing Licensing? R&D Product Sales
  • * ConventionalDevelopment costs Lab Test POC tests Our Technology Time to obtain the test results
  • * Total available market ~$20 billion Serviceable available Market ~ 2 billion Target market ~$645 million Source: American Association for Clinical Chemistry Source: Point of Care Testing, Biophoenix 2010Axis Shield (clinic based, fluidics Claros (sensitive fluidics device for HIVtests for HbA1c, CRP…)acquired detection using antibodies) acquiredAlere for $366 million (10/2011) for $46 million by OPKO (11/2011)
  • * * Pitch to other pharmaceutical and diagnostic companies * Develop prototype for the BEST targets in therapeutic drug monitoring to demonstrate our technology * Apply SBIRs to reduce technical risks * License the technology from the University of Illinois * Move into the Research Park at the University of Illinois through the I-Start program
  • Business Model Canvas #1 Yi Lu, Tian Lan Sweet Sensors Neil Kane Chris Sorensen Conferences Product R&DGlucose monitor At home Diabetics QC Product supports manufacturers Clinicians (in rural area) Marketing Convenient PatientKit manufacturers network/community Triage nurses Less exposure toReagent suppliers infectious diseases Pre-diabetics in the hospital Cheaper More frequent Retailers (Walgreen) IP Personnel Better indicator of Online vendors (Amazon) health (diabetic management) Direct sales Reagents Manufacture Disposable test kit (used repeatedly Licensing on a regular basis) FDA certification?
  • Business Model Canvas #2 Yi Lu, Tian Lan Sweet Sensors Neil Kane Chris Sorensen Conferences Product R&DGlucose monitor At home Diabetics * QC Marketing Product supports manufacturers Clinicians (in rural area) FDA approval for in Convenient PatientKit manufacturers vitro diagnostics network/community Triage nurses Less exposure toReagent suppliers infectious diseases Pre-diabetics in the hospital Cheaper IP Personnel More frequent Retailers (Walgreen) Better indicator of Online vendors (Amazon) KOL health (diabetic management) Direct sales Reagents Manufacture Disposable test kit (used repeatedly Licensing on a regular basis) FDA approval for in vitro diagnostics
  • Business Model Canvas #3 Yi Lu, Tian Lan Sweet Sensors Neil Kane 10-18-2011 Chris Sorensen Conferences Product R&D ImmediacyGlucose monitor At home Diabetics * QC Marketing Product supports manufacturers Clinicians (in rural area) FDA approval for in Convenient PatientKit manufacturers vitro diagnostics network/community Less exposure toReagent suppliers infectious diseases Pre-diabetics in the hospital Food safety and Cheaper security related IP Personnel More frequent Retailers (Walgreen) Better indicator of Online vendors (Amazon) KOL health (diabetic management) Reagents Manufacture Disposable test kit (used repeatedly Licensing on a regular basis) FDA approval for in vitro diagnostics
  • Business Model Canvas #4 Yi Lu, Tian Lan Sweet Sensors Neil Kane 10-25-2011 Chris Sorensen Conferences Product R&D ImmediacyGlucose monitor Out of clinic Diabetics * QC Marketing Product support manufacturers- Abbott? Clinicians (in rural area) FDA approval for in Convenient Patient vitro diagnostics network/community Pre-diabeticsKit manufacturers Food safety andReagent suppliers security related Cheaper Drug monitoring IP Personnel More frequent Retailers (Walgreen) Medical Products Distributors KOL Pharmaceutical Cos Reagents Disposable test kit (used repeatedly on a regular basis) Manufacture Reimbursement strategy Licensing FDA approval for in Licensing Sponsored development or JDA vitro diagnostics
  • Business Model Canvas #4 Yi Lu, Tian Lan Sweet Sensors Neil Kane 10-25-2011 Chris Sorensen Conferences Product R&D ImmediacyGlucose monitor Out of clinic Diabetics * QC Marketing Product support manufacturers- Abbott? Clinicians (in rural area) FDA approval for in Convenient Patient vitro diagnostics network/community Pre-diabeticsKit manufacturers Food safety andReagent suppliers security related Cheaper Drug monitoring KOL More frequent Retailers (Walgreen) IP Personnel Medical Products Distributors Pharmaceutical Cos Reagents Disposable test kit (used repeatedly on a regular basis) Manufacture Reimbursement strategy Licensing FDA approval for in Licensing Sponsored development or JDA vitro diagnostics
  • Business Model Canvas #5b Yi Lu, Tian Lan, Brian Wong Sweet Sensors Neil Kane 11-01-2011 Chris Sorensen Conferences R&DPharmaceutical Pharmaceutical * QCcompanies One to one companies for Immediacy Therapeutic DrugGlucometer/strip Long term Monitoring (TDM) Convenient monitoringmanufacturer and safer dosage Exclusive Pharmaceutical Cos IP Pharmaceutical Cos Personnel Licensing R&D Sales (to pharmaceutical companies)
  • Business Model Canvas #6 Yi Lu, Tian Lan, Brian Wong Sweet Sensors Neil Kane 11-01-2011 Chris Sorensen Conferences R&DPharmaceutical Pharmaceutical * QCcompanies One to one companies ImmediacyGlucometer/strip Convenient monitoring Long term Glucometer/stripmanufacturer and safer dosage manufacturerDiagnostics Exclusive Diagnosticcompanies companyContract research Contract research Pharmaceutical Cosorganization organization IP Pharmaceutical Cos Personnel Licensing R&D Sales (to pharmaceutical companies)
  • Business Model Canvas # 7 w/changes Yi Lu, Tian Lan, Brian Wong Sweet Sensors Neil Kane 11-08-2011 Chris Sorensen Conferences R&DPharmaceutical Pharmaceutical * QCcompanies Direct companies Immediacy PublicityGlucometer/strip Convenient monitoring Long term Glucometer/stripmanufacturer Insurance Reimbursement and safer dosage manufacturerDiagnostics Exclusive Diagnosticcompanies companies InexpensiveContract research Pharmaceutical Cos Contract research Pharmaceutical Cos Simpleorganizations organizations IP InvestorsGlucometer mfr Robust/extensibleStrip mfr Personnel Licensing Licensing? R&D Product Sales
  • Business Model Canvas # 8 Yi Lu, Tian Lan, Brian Wong Sweet Sensors Neil Kane 11-15-2011 Chris Sorensen Conferences R&DPharmaceutical Immediate results Pharmaceutical *companies Publicity companies Direct Convenient monitoringDiagnostics Insurance Reimbursement and safer dosage Long termcompanies Diagnostic Robust/extensible companiesContract researchorganizations Inexpensive Contract research organizations Simple Pharmaceutical Cos Pharmaceutical CosGlucometer mfr IP InvestorsStrip mfr Personnel Licensing Licensing? R&D Product Sales
  • * * NSF I-Corps program * The I-Corps teaching team
  • *
  • * GlucoSentientGlucose meter Pharmaceutical /manufacturer • Added value for diagnostic companies• Meter engineering meter manufacturers • Provide the target of• Strip design • Low cost, fast interest• FDA approval monitoring improves • Key customers clinical trials • Key market knowledge